Bromodomain Ligand 4

<strong>Bromodomain Ligand 4 </strong>_x000D_ <strong>Catalog number:</strong> B2019098_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 250 uL @ 20 µM_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> Bromodomain Ligand 4_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Shanmugam V, Muthukrishnan S. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach J Biomol Struct Dyn. 2023;41(23):14524-14539._x000D_ 2: Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B, Ding L. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses Acta Pharm Sin B. 2020 May;10(5):723-733._x000D_ 3: Min J, Mayasundari A, Keramatnia F, Jonchere B, Yang SW, Jarusiewicz J, Actis M, Das S, Young B, Slavish J, Yang L, Li Y, Fu X, Garrett SH, Yun MK, Li Z, Nithianantham S, Chai S, Chen T, Shelat A, Lee RE, Nishiguchi G, White SW, Roussel MF, Potts PR, Fischer M, Rankovic Z. Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs Angew Chem Int Ed Engl. 2021 Dec 13;60(51):26663-26670._x000D_ 4: Bursch KL, Goetz CJ, Jiao G, Nuñez R, Olp MD, Dhiman A, Khurana M, Zimmermann MT, Urrutia RA, Dykhuizen EC, Smith BC. Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression J Biol Chem. 2024 Apr;300(4):107146._x000D_ 5: Kim SL, Choi HS, Lee DS. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells Cell Commun Signal. 2023 Nov 3;21(1):315._x000D_ 6: Kaur SD, Bedi N, Kumar D, Kapoor DN. PROTACs: Promising approach for anticancer therapy Cancer Lett. 2023 Mar 1;556:216065._x000D_ 7: Habash NW, Sehrawat TS, Shah VH, Cao S. Epigenetics of alcohol-related liver diseases JHEP Rep. 2022 Mar 10;4(5):100466._x000D_ 8: Xue G, Xie J, Hinterndorfer M, Cigler M, Dötsch L, Imrichova H, Lampe P, Cheng X, Adariani SR, Winter GE, Waldmann H. Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype Nat Commun. 2023 Nov 30;14(1):7908._x000D_ 9: Ibrahim MAA, Abdelhamid MMH, Abdeljawaad KAA, Abdelrahman AHM, Mekhemer GAH, Sidhom PA, Sayed SRM, Paré PW, Hegazy MF, Shoeib T. Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation Molecules. 2023 Jul 28;28(15):5713._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34105560">10: Guest EE, Pickett SD, Hirst JD. Structural variation of protein-ligand complexes of the first bromodomain of BRD4 Org Biomol Chem. 2021 Jun 30;19(25):5632-5641. </a>_x000D_ _x000D_ <strong>Products Related to Bromodomain Ligand 4 can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>